Keisuke Ishizawa
Papers
1
Total Citations
17
H-Index
1
About
Keisuke Ishizawa is a leading pharmacoepidemiologist whose research focuses on the safety and real-world effectiveness of medications, with a particular emphasis on oncology and chronic disease management. His work systematically evaluates adverse drug reactions using large-scale spontaneous reporting databases, providing critical insights into drug safety profiles that may not emerge in clinical trials. One of his most cited studies, "Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens," analyzed global adverse event data from 2002 to 2018, revealing significant safety signals in prostate cancer treatments during a period when patient numbers doubled from roughly 679,000 to over 1.27 million. This work, which has garnered 17 citations, exemplifies his ability to translate big data into actionable clinical warnings. Ishizawa’s contributions are vital for clinicians and regulators, helping to balance therapeutic benefits against rare but serious risks. His research continues to shape safer prescribing practices, making him a key figure in evidence-based pharmacovigilance and a trusted voice for students and researchers navigating the complexities of drug safety.
Research Focus
Key Achievements
Top Papers
- 1